Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) and Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.
Profitability
This table compares Foghorn Therapeutics and Amylyx Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Foghorn Therapeutics | 8.40% | -10.63% | 4.53% |
| Amylyx Pharmaceuticals | N/A | -41.54% | -38.91% |
Earnings and Valuation
This table compares Foghorn Therapeutics and Amylyx Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Foghorn Therapeutics | $30.91 million | 3.66 | -$74.28 million | ($0.98) | -1.94 |
| Amylyx Pharmaceuticals | $87.37 million | 45.81 | -$144.74 million | ($1.44) | -21.62 |
Foghorn Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Foghorn Therapeutics has a beta of 3.22, indicating that its stock price is 222% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500.
Insider & Institutional Ownership
61.5% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent recommendations for Foghorn Therapeutics and Amylyx Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Foghorn Therapeutics | 1 | 6 | 4 | 0 | 2.27 |
| Amylyx Pharmaceuticals | 1 | 0 | 6 | 2 | 3.00 |
Foghorn Therapeutics currently has a consensus price target of $6.14, indicating a potential upside of 222.46%. Amylyx Pharmaceuticals has a consensus price target of $43.71, indicating a potential upside of 40.42%. Given Foghorn Therapeutics’ higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Amylyx Pharmaceuticals.
Summary
Foghorn Therapeutics beats Amylyx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Foghorn Therapeutics
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that target the chromatin regulatory system, which controls how DNA is packaged and how genes are expressed. The company’s research is directed primarily toward cancer therapies, particularly for tumors driven by abnormalities in chromatin-remodeling proteins. Foghorn uses its proprietary Gene Traffic Control platform to identify and develop small-molecule treatments designed to modulate chromatin-regulating complexes.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
